Bach-Yen Nguyen

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel, David A. Cooper, Princy Kumar et al. · New England Journal of Medicine · 2008 · 683 citations · Full text

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

David Roth, David R. Nelson, Annette Bruchfeld et al. · The Lancet · 2015 · 663 citations · Full text

Hepatic Disorders, Hepatitis C, Viral Hepatitis +10

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin et al. · The Lancet · 2009 · 619 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +8

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Beatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama et al. · The Lancet · 2007 · 566 citations · Full text

Multidrug-resistant Virus, Treatment And Prevention, Antiviral Drug Development +9

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

David A. Cooper, Roy T. Steigbigel, José M. Gatell et al. · New England Journal of Medicine · 2008 · 505 citations · Full text